The primary objective of this study is to evaluate the efficacy, safety, and tolerability of
treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC)
for 8 weeks and of treatment with sofosbuvir/velpatasvir (SOF/VEL) FDC for 12 weeks in
participants naive to direct-acting antivirals (DAA) with chronic genotype 3 hepatitis C
virus (HCV) infection and cirrhosis.